NCT06936098

Brief Summary

Colorectal cancer (CRC) is a leading cause of mortality in China, with metastasis significantly contributing to poor outcomes. Histopathological growth patterns (HGPs) in colorectal liver metastasis (CRLM) provide vital prognostic insights, yet the limited number of pathologists highlights the need for auxiliary diagnostic tools. Recent advancements in artificial intelligence (AI) have demonstrated potential in enhancing diagnostic precision, prompting the development of specialized AI models like COFFEE to improve the classification and management of HGPs in CRLM patients. This study aims to develop and validate a Transformer-based deep learning model, COFFEE, for the classification of colorectal cancer subtypes using whole slide images (WSIs) from patients diagnosed with colorectal cancer liver metastasis. The model is pre-trained using self-supervised learning (DINO) on WSIs from the TCGA-COAD cohort, utilizing a Vision Transformer (ViT) architecture to extract 384-dimensional feature vectors from 256×256 pixel patches. The COFFEE model integrates a Transformer-based Multiple Instance Learning (TransMIL) framework, incorporating multi-head self-attention and Pyramid Position Encoding Generator (PPEG) modules to aggregate spatial and morphological information. The study includes training, testing, and prospective validation cohorts and evaluates the performance of the model in both binary and multi-class classification settings, as well as its potential to assist pathologists in clinical workflows.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
431

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 22, 2023

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 6, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 6, 2024

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

April 3, 2025

Completed
17 days until next milestone

First Posted

Study publicly available on registry

April 20, 2025

Completed
Last Updated

April 20, 2025

Status Verified

April 1, 2025

Enrollment Period

10 months

First QC Date

April 3, 2025

Last Update Submit

April 13, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Classification Accuracy (%) of the COFFEE AI Model in Binary Identification of Histopathological Growth Patterns (HGPs) in CRLM Using Whole Slide Images

    This outcome measures the diagnostic classification accuracy of the COFFEE AI model in detecting histopathological growth patterns (HGPs) in patients with colorectal cancer liver metastasis (CRLM). Accuracy is defined as the proportion of correctly predicted HGP labels compared to the ground truth labels determined by consensus of expert pathologists. The analysis includes binary classification (desmoplastic vs. non-desmoplastic). Accuracy will be calculated as: Accuracy = Total number of predictions / Number of correct predictions×100%. The outcome will be assessed using digital whole slide images obtained from liver metastasis specimens collected during surgery. Model performance will be evaluated 6 months post-surgery in a prospective validation cohort.

    6 months post-surgery (for prospective cohort)

Secondary Outcomes (1)

  • Classification Accuracy (%) of the COFFEE AI Model in Multi-Class Identification of Histopathological Growth Patterns (HGPs) in CRLM Using Whole Slide Images

    6 months post-surgery (for prospective cohort)

Other Outcomes (4)

  • Progression-Free Survival (PFS, in months) in Colorectal Cancer Liver Metastasis (CRLM) Patients Stratified by AI-based Histopathological Growth Pattern (HGP) Classification

    Up to 3 years post-surgery

  • Overall Survival (OS, in months) in Colorectal Cancer Liver Metastasis (CRLM) Patients Stratified by AI-based Histopathological Growth Pattern (HGP) Classification

    Up to 3 years post-surgery

  • Time to Diagnosis (in minutes) by Pathologists With and Without AI-Assisted COFFEE Model in CRLM HGP Classification

    During the prospective trial period (6 months)

  • +1 more other outcomes

Study Arms (3)

Surgical pathology slides from the SAHSYSU, 1,994 WSIs from 297 slides dated July 3, 2013.

This group includes 297 patients with colorectal cancer liver metastasis (CRLM), from which 1,994 whole slide images (WSIs) were collected. These slides were used for developing and testing the COFFEE AI model for histopathological growth pattern (HGP) classification, providing valuable insights for tumor characterization and prognosis.

Procedure: CRLM surgery

Surgical pathology slides from the SAHSYSU , 972 WSIs from 104 patients dated April 21, 2023.

This cohort contains 104 patients diagnosed with CRLM. 972 WSIs were collected to validate the COFFEE model on a more recent dataset, evaluating the model's performance in both binary and four-class HGP classifications.

Procedure: CRLM surgery

Surgical pathology slides from the SAHSYSU, 114 WSIs from 30 patients dated 2024.

This prospective cohort consists of 30 patients with CRLM, from which 114 WSIs were obtained in 2024. The cohort was used to assess the clinical applicability of the COFFEE AI model through a prospective trial, comparing the diagnostic performance of pathologists with and without AI assistance.

Procedure: CRLM surgery

Interventions

CRLM surgeryPROCEDURE

Surgical resection of colorectal cancer liver metastasis (CRLM) involves the removal of metastatic lesions from the liver. This procedure is aimed at improving survival rates and reducing tumor burden in patients diagnosed with CRLM. The resection is performed to treat liver metastasis, and clinical outcomes, such as progression-free survival (PFS) and overall survival (OS), are assessed post-surgery to determine treatment efficacy.

Surgical pathology slides from the SAHSYSU , 972 WSIs from 104 patients dated April 21, 2023.Surgical pathology slides from the SAHSYSU, 1,994 WSIs from 297 slides dated July 3, 2013.Surgical pathology slides from the SAHSYSU, 114 WSIs from 30 patients dated 2024.

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study involved 431 patients with colorectal cancer liver metastasis, all undergoing surgery at the Sixth Affiliated Hospital of Sun Yat-sen University. The cohort consisted of 297 patients in the training set and 104 patients in the testing set.

You may qualify if:

  • Patients diagnosed with colorectal cancer liver metastasis (CRLM) undergoing surgical treatment;
  • The maximum diameter of resected metastatic lesions should be ≥ 2 cm;
  • Availability of pathology slides along with baseline clinical, biological, and pathological features.

You may not qualify if:

  • Tissue sections obtained from biopsy specimens;
  • Absence of viable tumor tissue in metastatic lesions;
  • Lesions previously treated with ablation followed by surgical resection, resulting in inadequate tissue slide quality.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ethics Committee of the Sixth Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, 510655, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

This study recruited 431 colorectal cancer liver metastasis patients who underwent surgery at the Sixth Affiliated Hospital of Sun Yat-sen University (SAHSYSU), with liver metastasis samples from the hospital's archives. The training dataset included 1,994 whole slide images (WSIs) from 297 patients (batch dated July 3, 2013), and the testing dataset contained 972 WSIs from 104 patients (batch dated April 21, 2023). In 2024, two prospective experiments were conducted with 114 WSIs from 30 patients. One experiment involved a human-AI competition, where nine pathologists and AI independently interpreted WSIs for binary and quaternary classifications. The other assessed AI-assisted classification, where nine pathologists used AI support for the same tasks. Both experiments aimed to evaluate the model's performance and clinical applicability.

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending Physician

Study Record Dates

First Submitted

April 3, 2025

First Posted

April 20, 2025

Study Start

May 22, 2023

Primary Completion

March 6, 2024

Study Completion

March 6, 2024

Last Updated

April 20, 2025

Record last verified: 2025-04

Locations